Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||HER-2/neu intracellular domain protein + Polysaccharide-K + Trastuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HER-2/neu intracellular domain protein||HER-2 ICD Peptide|HER-2-neu ICD Protein||HER-2/neu intracellular domain protein is the cytoplasmic domain of the Her-2 protein, which may enhance the T-cell response against Her-2 expressing tumor cells when administered with trastuzumab (NCI Drug Dictionary).|
|Polysaccharide-K||Krestin|PSK||Krestin (polysaccharide-K) is a mushroom-derived immunomodulator that has been demonstrated to reduce immunosuppression and enhance anti-tumor immunity. Krestin has also been shown to reduce proliferation and induce apoptosis in tumor cells (PMID: 22139128).|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 57||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|